James Sabry - Chugai Pharmaceutical Director
CHGCF Stock | USD 39.14 2.42 5.82% |
Director
Dr. James Sabry was serving as Director in Chugai Pharmaceutical Co., Ltd. since March 2019. He is also working in Roche Pharmaceuticals. since 2019.
Age | 59 |
Tenure | 5 years |
Professional Marks | Ph.D |
Phone | 81 3 3281 6611 |
Web | https://www.chugai-pharm.co.jp |
Chugai Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.1956 % which means that it generated a profit of $0.1956 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2867 %, meaning that it generated $0.2867 on every $100 dollars invested by stockholders. Chugai Pharmaceutical's management efficiency ratios could be used to measure how well Chugai Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
John Noseworthy | Merck Company | 66 | |
Beatrice Mauro | Roche Holding | 49 | |
Mary Coe | Merck Company | 54 | |
Thomas Glocer | Merck Company | 61 | |
Christine Seidman | Merck Company | 68 | |
David Hoover | Eli Lilly And | 72 | |
Baroness Vadera | AstraZeneca PLC ADR | 52 | |
William Harrison | Merck Company | 70 | |
Inge Thulin | Merck Company | 67 | |
Leslie Brun | Merck Company | 68 | |
Hubert Joly | Johnson Johnson | 61 | |
Frans Houten | Novartis AG ADR | 61 | |
Genevieve Berger | AstraZeneca PLC ADR | 64 | |
Mark McClellan | Johnson Johnson | 57 | |
Charles Prince | Johnson Johnson | 71 | |
Peter Wendell | Merck Company | 70 | |
Richard Lifton | Roche Holding | 65 | |
Patricia Russo | Merck Company | 68 | |
Dimitri Azar | Novartis AG ADR | 59 | |
Kathi Seifert | Eli Lilly And | 70 | |
Eugene Washington | Johnson Johnson | 67 |
Management Performance
Chugai Pharmaceutical Leadership Team
Elected by the shareholders, the Chugai Pharmaceutical's board of directors comprises two types of representatives: Chugai Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chugai. The board's role is to monitor Chugai Pharmaceutical's management team and ensure that shareholders' interests are well served. Chugai Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chugai Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Osamu Nagayama, Chairman and CEO | ||
Masayuki Oku, Independent Director | ||
Franz Humer, Independent Director | ||
Sophie KornowskiBonnet, Independent Director | ||
Yasuo Ikeda, Independent Director | ||
Harunori Yamazaki, Manager of Accounting Group in Finance & Accounting Unit | ||
Yoshiyuki Yano, Executive Officer, Director of Human Resources | ||
William Anderson, Director | ||
Tatsuro Kosaka, President, COO and Representative Director | ||
Motoo Ueno, Vice Chairman of the Board, Representative Director | ||
Toshihiko Komori, Executive Officer, Assistant Manager of Project & Life Cycle Management Unit, Director of R&D Portfolio | ||
Mamoru Togashi, Executive Officer, Director of Human Resources, Senior Manager of Human Resources Division | ||
James Sabry, Director | ||
Yutaka Tanaka, Managing Executive Officer, Manager of Life Circle Management and Marketing Unit | ||
Daniel ODay, Independent Director | ||
Minoru Watanabe, Executive Officer, Director of Business Planning | ||
Tadahiko Sato, Executive Officer, Senior Manager of Tokyo 1st Office | ||
Shinji Hidaka, Executive Officer, Deputy Chief Director of Sales, Manager of Primary Unit | ||
Tetsuya Yamaguchi, Executive Officer, Director of Business Development | ||
Hitoshi Kuboniwa, Executive Officer, Chief Director of Pharmaceutics Producing | ||
Masaaki Tohaya, Managing Executive Officer, Chief Director of Sales | ||
Tsunanori Sato, Executive Officer, Chief Director of Sales | ||
Toshiaki Itagaki, VP and General Manager of Fin. and Accounting Department | ||
Junichi Ebihara, VP and General Manager of Legal Department | ||
Toshiya Sasai, Exec Department | ||
Koichi Nishikawa, Executive Officer, Deputy Chief Director of Sales, Director of Marketing Planning | ||
Osamu Okuda, Executive Officer, Director of Business Planning | ||
Yoshiaki Ohashi, Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Management Unit | ||
Yoko Kitagawa, Manager of Consolidated Financial Group in Finance & Accounting Unit | ||
Christoph Franz, Director | ||
Shinya Unno, Managing Executive Officer, Director of Business Planning | ||
Hiroyuki Matsumoto, Executive Officer, Senior Manager of South Kanto Office in Main Sales Unit | ||
Satoko Shisai, Executive Officer, Senior Manager of IT | ||
Keiji Kono, Executive Officer, Senior Manager of IT Division | ||
Hisafumi Okabe, VP and General Manager of Research Division | ||
Hisanori Takanashi, Executive Officer, Chief Director of Clinical Development | ||
Hiroshi Murata, Executive Officer, Chief Director of Pharmaceutical Technology | ||
Yoichiro Ichimaru, Independent Director | ||
Yoshio Itaya, CFO, Executive VP, General Manager of Fin. Supervisory Division and Director | ||
Masahiko Uchida, Gen Department | ||
Yasushi Ito, Executive Officer, Chief Director of Clinical Development | ||
Susumu Kato, Executive Officer, Senior Manager of Tokyo First Office | ||
Mitsuru Kikuchi, Managing Executive Officer, Director of External Investigation |
Chugai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Chugai Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.29 | |||
Return On Asset | 0.2 | |||
Profit Margin | 0.30 % | |||
Operating Margin | 0.42 % | |||
Current Valuation | 39.67 B | |||
Shares Outstanding | 1.64 B | |||
Shares Owned By Insiders | 59.99 % | |||
Shares Owned By Institutions | 18.71 % | |||
Price To Earning | 19.49 X | |||
Price To Book | 3.95 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Chugai Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Chugai Pharmaceutical's short interest history, or implied volatility extrapolated from Chugai Pharmaceutical options trading.
Pair Trading with Chugai Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chugai Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chugai Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Chugai Pink Sheet
0.78 | EC | Ecopetrol SA ADR Report 3rd of April 2024 | PairCorr |
0.56 | PTAIF | PT Astra International | PairCorr |
0.51 | TLK | Telkom Indonesia Tbk Financial Report 26th of April 2024 | PairCorr |
0.47 | NVSEF | Novartis AG | PairCorr |
The ability to find closely correlated positions to Chugai Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chugai Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chugai Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chugai Pharmaceutical Co to buy it.
The correlation of Chugai Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chugai Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chugai Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chugai Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chugai Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Chugai Pharmaceutical information on this page should be used as a complementary analysis to other Chugai Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Chugai Pink Sheet analysis
When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |